Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Hyman, David M
| Class:Id | Person:9646802 |
|---|---|
| _displayName | Hyman, David M |
| _timestamp | 2019-05-28 20:03:44 |
| created | [InstanceEdit:9646793] Orlic-Milacic, Marija, 2019-05-28 |
| firstname | David M |
| initial | DM |
| surname | Hyman |
| (author) | [LiteratureReference:9646787] Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) [LiteratureReference:9646931] Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [LiteratureReference:9647026] An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Hyman, David M (9646802)
